KALA BIO to Host Virtual Key Opinion Leader (KOL) Event to Discuss the Potential of KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)

Core Insights - KALA BIO, Inc. is hosting a webcast event on July 16, 2025, to discuss the potential of KPI-012 for treating persistent corneal epithelial defect (PCED) [1][2] - The event will feature presentations from Key Opinion Leaders (KOLs) covering the disease overview, unmet needs, and insights into KPI-012 and the CHASE clinical trial [2] Company Overview - KALA BIO is a clinical-stage biopharmaceutical company focused on innovative therapies for rare and severe eye diseases [4] - The company's lead product candidate, KPI-012, is based on a proprietary mesenchymal stem cell secretome (MSC-S) platform and aims to address impaired corneal healing [4] - KPI-012 has received Orphan Drug and Fast Track designations from the U.S. FDA for the treatment of PCED [4] Future Developments - KALA BIO is exploring the potential of KPI-012 for Limbal Stem Cell Deficiency and other rare corneal diseases, as well as preclinical studies for retinal degenerative diseases [4]